Genomic Vision develops genetic screening tests for diagnostics and research. In the aftermath of the Myriad ruling, how can it use IP to develop market share? LSIPR spoke to chief executive Aaron Bensimon to find out.
When the Supreme Court decided earlier this year that isolated genetic material is not patent-eligible, it opened up the genetic screening market, inevitably introducing a new battleground for asserting IP rights on diagnostic technologies.
Many companies, including Ambry Genetics and Gene by Gene, started offering their own tests that could identify genetic disorders and susceptibility to certain diseases immediately after the June 13 ruling, and a series of patent infringement cases were filed among the companies soon after, as each tried to muscle in to the market.
French biotechnology company Genomic Vision offers a novel method of genome analysis. Its proprietary technology, which it calls molecular combing, allows researchers to view the genome at a high resolution and identify genetic anomalies within it.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Genomic Vision, IP strategy, genetic screening, Myriad, cancer